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INTRODUCTION: 
In the pharmaceutical industries, recombinant DNA 
technology has brought about a rapid growth and 
advancement in therapeutics available for human use1. 
This article focuses on recombinant DNA-technology 
and their application in modern therapeutics. Modern 
researches are ongoing to investigate the function of a 
particular gene. A gene is responsible for production of 
particular type of protein which, in turns, plays an 
important role in determination of final phenotype of an 
organism. Thus by r-DNA technology, we can reproduce 
desired biological products2. Recombinant DNA is a 
DNA which is made by splicing of a foreign DNA, and 
rejoining fragments into a small replicating molecule.  
DNA from two or more sources are joint in to a single r-
DNA. DNA from both sources are treated with 
restriction endonuclease, which cut on same site on both 
DNA molecules, 5’GGATCC3’, 3’CCTAGG5’. 
Overhanging pieces at the ends of single stranded DNA 
are called “sticky ends”, because they may base pair with 
any DNA molecule containing the complementary sticky 
ends. In above case both pairs with other in mixture since 
they are complementary. 
DNA ligase covalently joint two pieces of DNA to form 
r-DNA molecule. Clones of r-DNA are synthesizes, in 
vitro, by the process called polymerase chain reaction 
(PCR). Recombinant DNA then produced desired 
biological product. In vivo cloning of r- DNA can be 
carried out by unicellular microbes like E. coli, yeast and 
mammalian cells in tissue culture. In each case r-DNA 
must be introduced in cell for replication and expression. 
DNA vector is used for r-DNA transfer in to organism3, 4, 
5.  
Vectors 
Bacterial plasmid is the most commonly used vector. 
Plasmids used in genetic engineering are under control; 
their replication is totally independent of chromosomal 
replication. These plasmids may be present in copies of 
10-700 per cell. The most popular plasmid is pUC18. 
Bacterial plasmids cannot accept DNA strands larger 
than 5000 base pairs; hence they are restricted to cloning 
DNA ≤5000 base pairs. 
Many viruses also serve as vector for bacterial and 
mammalian cell. Bacteriophage lambda virus can 
incorporate up to 15-16 kilobases of DNA segment. A 
central one-third of its genome is normally not required 
for infection and therefore can be replaced by foreign 
DNA6.  
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ABSTRACT: 
Recombinant DNA-technology is one further step of genetic engineering, which enable us to mass production of safe, pure and 
effective biological products. Recombinant DNA is artificially created from two or more DNA incorporated into a single 
molecule. Genetic engineering, recombinant DNA technology, genetic modification/manipulation and gene splicing are terms 
that are applied to the direct manipulation of an organism’s gene. Recombinant DNA are used to produce biochemical’s such 
as hormones of therapeutic interest, haemopoietic growth factors, blood coagulation products, thrombolytic agents, 
anticoagulants, interferon, interleukins and therapeutic enzymes.  The biochemically derived biochemical is large extracellular 
proteins for use in either chronic replacement therapies or for the treatment of life threatening indications. This article focuses 
on basic concepts behind the recombinant DNA technique and current trend in recombinant DNA technology.   
Key Words: Recombinant DNA-technology, genetic engineering, thrombolytic agents, anticoagulants, interferon, interleukins.    
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Figure 1: Making recombinant DNA(r-DNA): An overview 
  
RECOMBINANT DNA TECHNOLOGY: 
METHOD
7, 8, 9, 10
:  
1. ISOLATION OF GENE: 
The desired gene responsible for production of particular 
biological product is isolated from cell. The procedure 
for isolation of DNA depends on the nature of donor. 
Two enzymes are very important in DNA isolation and r-
DNA synthesis; restriction endonuclease and DNA 
ligase. Restriction endonuclease recognizes a specific 
nucleotide sequence on DNA molecule, called restriction 
site and cleave DNA at this site. DNA ligase is 
responsible for joining two pieces of DNA by forming 
phosphodiester bonds.     
2. PREPARATION OF RECOMBINANT 
DNA: 
In 1973, two scientists named Boyer and Cohen 
developed a way to transfer DNA from one organism cell 
into DNA of bacteria. This provides roadmap for 
recombinant DNA technology4. The circular plasmid 
vector from bacterial cell is removed, and Special 
proteins are used to cut the plasmid ring to open its ring.     
3. INCERTION OF DNA INTO PLASMID: 
The desired DNA from host is inserted into open vector 
plasmid DNA ring. DNA ligase is required to seal the 
gaps. These enzymes covalently bonded two strands and 
generate a circular DNA molecule. The most commonly 
used DNA ligase, in the labs, is derived from 
bacteriophase T4.  
4. INCERTION OF PLASMID BACK INTO 
BACTERIAL CELL: 
Circular DNA molecule with desired host gene is 
transferred into bacterial cell. As plasmid is natural part 
of bacterial cell, it is auto accepted by bacteria. Now the 
reformed bacterial cell has host gene from different 
organism, this is called recombinant bacterial cell, and 
used for production of desired biological products.   
5. PLASMID MULTIPLICATION11: 
The inserted plasmid i.e. recombinant plasmid, can 
multiply in bacterial cell make several copies of wanted 
gene. Now these copies can transfer to many bacterial 
cells. Also, when bacterial cell reproduce by dividing, 
the recombinant plasmid reproduced in newly generated 
cell. Now, these cells are used for mass production of 
desired protein. The protein that is produced by r-DNA 
technology is purified and used for medicinal and 
industrial purpose.  
 
Maurya et al                                     Journal of Drug Delivery & Therapeutics; 2014, 4(4), 104-109 106 
© 2011-14, JDDT. All Rights Reserved                                                 ISSN: 2250-1177                                               CODEN (USA): JDDTAO 
 
Figure 2: Method for generating a chimeric DNA plasmid containing genes derived from foreign DNA. (From S. N. 
Cohen, “The Manipulation of Genes.” Copyright © 1975 by Scientific American, Inc. All rights reserved). 
 
APPLICATION OF RECOMBINANT DNA 
TECHNOLOGY IN HUMAN THERAPEUTICS: 
1. HORMONES: 
Diabetes mellitus characterized by hyperglycemia is 
most common disease worldwide. Hyperglycemia is a 
result of defects in insulin secretion, action or both. 
Disease can be treated by administration of recombinant 
insulin produced by         S. cerevisae or E. coli, which is 
structurally similar as human insulin. It provides rapid 
absorption when compared to regular human insulin13.  
It provides long peak less action with better effects 
during down hours14.  
Insulin glargine is a, long acting insulin structurally 
differs from human insulin at 21 position, where glycine 
is replaced by aspargine15.  
Insulin lispro, produced by E. coli, differ from human 
insulin by transposition of proline and lysine at 28 and 
29 positions in beta chain16.  
Insulin glulicin is rapid parenteral hypoglycemic 
produced by E. coli, differ from human insulin by 
replacing aspargin by lysine at B3and lysine at B26 is 
replaced by glutamic acid17.  
Recombinant follicle stimulating hormone (rFSH) and 
recombinant human chorionicgonadotropin (rhuCG) are 
produced by CHO cells, use to treat the infertility in 
humans18,19 . 
Somatotropin produced by E. coli is a recombinant 
growth hormone used to treat growth hormone 
deficiency. It differ from human growth hormone by 
containing additional methionin at N-terminus of 
molecule
20
.
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Table 1: Some r-DNA products approved by FDA for human application12 
Therapeutic 
category  
Product  Expression host  Abbreviated indication  
Hormone of 
therapeutic interest  
Human insulin 
 
Insulin aspart  
Insulin glargine  
Insulin lispro  
Insulin glulisine  
Human 
choriogonadotropin  
 
 
 
Follicle-stimulating 
hormone  
Luteinizing hormone  
Somatotrophin  
E. coli/   S. 
cerevisiae  
S. cerevisiae  
E. coli 
E .coli 
E. coli 
CHO cell 
 
 
 
 
CHO cell 
CHO cell 
E. coli 
Treatment of diabetes 
 
Treatment of diabetes  
Treatment of diabetes  
Treatment of diabetes  
Treatment of diabetes  
Treatment of women undergoing superovulation 
prior to assisted reproductive techniques such as 
in vitro fertilization  
 
 
Treatment of infertility 
Induction of ovulation 
Treatment of deficiency of growth failure  
Haemopoietic 
growth factors  
Erythropoietin alpha  
 
Erythropoietin beta   
 
Erythropoietin omega  
  
 
Darbepoetin 
 
 
Filgrastim  
 
 
 
Surgramostim  
CHO cell 
 
CHO cell 
 
BHK cell 
 
 
CHO cell 
 
 
E. coli 
 
 
 
S. cerevisiae  
 
Treatment of anemia associated with renal 
failure, HIV infection, cancer.  
Treatment of anemia associated with renal 
failure.  
Treatment of anemia associated with renal 
failure, cancer.  
 
Treatment of anemia associated with renal 
failure, cancer. 
 
Reduction in duration of neutropenia and 
incidence of febrile neutropenia in patients 
treated with cytotoxic chemotherapy for 
malignancy  
Treatment of neutrophil recovery   
Therapeutic 
enzymes  
Dorsase alpha 
Glucocerebrosidase  
CHO cells  
CHO cells  
Cystic fibrosis  
Replacement therapy in patients with Gaucher 
disease  
Human interleukins  Interleukin-2 
Interleukin-11 
E. coli  
E. coli  
Renal cell carcinoma  
Treatment of thrombocytopenia  
Anticoagulants  Lepirudin  
 
Desirudin  
S. cerevisiae  
  
S. cerevisiae 
Anticoagulation therapy for heparin associated 
thrombocytopenia  
Prevention of venous thrombosis  
Human interferon  Interferon alpha-2b  
 
Interferon beta-1b  
Interferon gamma  
E. coli  
 
E. coli  
E. coli 
Treatment of hairy cell leukaemia, chronic 
hepatitis B and C, AIDS, cancer   
Treatment of multiple sclerosis 
Chronic granulomatous disease  
Human blood 
coagulation factors  
Factor VIII  
Factor IX    
Factor VII A  
CHO cells  
CHO cells  
BHK cell  
Treatment of haemophilia A  
Treatment of haemophilia B 
Treatment of haemophilia A and B 
Thrombolytic 
agents  
Alteplase  
Reteplase  
Tenecteplase  
Saruplase  
CHO cells  
E. coli  
CHO cells  
E. coli   
Treatment of acute myocardial infarction  
Treatment of acute myocardial infarction  
Treatment of acute myocardial infarction 
Thrombolytic therapy for acute myocardial 
infarction  
 
 
2. HAEMOPOIETIC GROWTH FACTORS:  
Recombinant human erythropoietin (rhuEPO)  is use to 
treat HIV infection, cancer renal failure and surgery. 
Epoetin alpha, epoetin beta and epoetin omega are three     
 rhuEPO available for human application21.  
Darbepoetin alfa has been developed for the treatment of 
anemia22.  
3. BLOOD COAGULATION FACTOR:  
Deficiency   of human coagulation factor VIII causes 
hemophilia A, the most common inherited bleeding 
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disorder. Recombinant human factor VIII, produced in 
CHO cell provides temporary control on bleeding23,24.  
4. THROMBOLYTIC AGENTS:   
Tissue plasminogen activator (TPA) is used to dissolve 
thrombus in blood vessels. Alteplase a recombinant 
tissue plasminogen activator (rTPA) stimulates 
thrombolysis by converting plasminogen to plasmin. 
Now, this is treatment of choice for acute myocardial 
infarction (AMI)25.  
5. ANTICOAGULANTS:  
Lipirudin, a recombinant derivative of leech 
anticoagulant hirudin, is used for treatment of heparin 
induced thrombocytopenia, produced by using yeast 
cells26.  
6. HUMAN INTERFERON:  
The three recombinant human interferons (rhuIFN) are 
alpha, beta and gamma. Recombinant human interferon 
are indicated for hairy cell leukemia and chronic 
granulomatous disease27,28.  
7. HUMAN INTERLEUKINS: 
The recombinant human interleukins (rhuIL)-2 produced 
in E. coli, is indicated for treatment of renal cell 
carcinoma and melanoma29, 30.  
8. THERAPUTIC ENZYMES:  
Deficiency of glucocerebrocidase enzyme causes 
Gauchers’ disease. Recombinant glucocerebrocidase is 
indicated for treatment of Gauchers’ disease31.  
CONCLUSION:  
Recombinant DNA technology has indeed made 
tremendous breakthrough in the discovery of advance 
therapeutics. Besides the products approved by FDA for 
human use, several products are undergoing clinical 
trials. Products are developed in the field of 
haematology, endocrinology and oncology.  The 
development of this new technology has resulted into 
production of large amount of biochemically defined 
proteins of medical significance and created an enormous 
potential for pharmaceutical industries. The 
biochemically derived therapeutics is large extracellular 
proteins for use in either chronic replacement therapies 
or for the treatment of life threatening indications. 
Recombinant DNA technology has also an important role 
in forensic science in identification of criminals, DNA 
profiling. Use of recombinant DNA, important genes, 
especially mammalian genes, could be amplified and 
cloned in foreign organisms. This provided a different 
approach to complex biological problem-solving. This 
cell-based, protein manufacturing technologies offer 
many advantages, producing recombinant 
pharmaceutically important proteins which are safe and 
effective for human application.  
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